We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
FUJIREBIO

Download Mobile App




Adsorption Procedure Enhances Efficiency of Drug Transport

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: Combining a nanocarrier with antibodies under acidic conditions results in the antibodies attaching to the drug carrier in a stable way. This makes it possible for nanocarriers to target diseased tissue (Photo courtesy of Stefan Schuhmacher).
Image: Combining a nanocarrier with antibodies under acidic conditions results in the antibodies attaching to the drug carrier in a stable way. This makes it possible for nanocarriers to target diseased tissue (Photo courtesy of Stefan Schuhmacher).
A simple adsorption procedure enhances the efficiency of nanocarrier transport of toxic drugs to tumors.

To promote drug delivery to exact sites and cell types, the surface of nanocarriers is functionalized with targeting antibodies or ligands, typically coupled by covalent chemistry. Once the nanocarrier is exposed to biological fluid such as plasma, however, its surface is inevitably covered with various biomolecules forming a protein corona, which masks the targeting ability of the nanoparticle.

To get around the protein-masking problem, investigators at Johannes Gutenberg University Mainz (Germany) developed a pre-adsorption process to attach targeting antibodies to the surface of the nanocarrier.

The investigators reported in the June 18, 2018, online edition of the journal Nature Nanotechnology that pre-adsorbed antibodies remained functional and were not completely exchanged or covered by the biomolecular corona, whereas coupled antibodies were more affected by this shielding.

"Up to now, we have always had to use elaborate chemical methods to bind these antibodies to nanocapsules," said senior author Dr. Volker Mailänder, head of the nanocarriers for medical applications group at the Johannes Gutenberg University Mainz. "We have now been able to show that all that you need to do is to combine antibodies and nanocapsules together in an acidified solution."

Related Links:
Johannes Gutenberg University Mainz

New
Gold Supplier
Nucleic Acid Extractor (Magnetic Bead Method)
Singu20
Flu + SARS Antigen Test
Sofia 2 Flu + SARS Antigen FIA
New
Silver Supplier
SARS-CoV-2 RT-PCR Assay
ErbaMDx SARS-COV-2 RT-PCR Kit
New
Silver Supplier
Nucleic Acid Extractor
Pre-NAT II

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.